Nifty Pharma likely to weaken in near-term; adopt sell on rise approach

Nifty Pharma is weak on hourly charts. Traders should be cautious and sell on every rise, while Nifty Energy Index is in a range-bound phase, says Ravi Nathani

markets, stock markets, stock market, trading, technical analysis, technical, trading
Ravi Nathani Mumbai
2 min read Last Updated : Jun 09 2023 | 7:11 AM IST
Nifty Energy Index

Last close: 24,215

On the charts, the Nifty Energy Index is in a range-bound phase. The upper range is around 24,317, while the lower range is near 23,692. A breakout above or below these levels would indicate a shift in the market trend. Given the current range-bound conditions, the best trading strategy would be to buy near the support levels and sell near the resistance levels.

Traders should closely monitor the price action and wait for a breakout before taking larger positions. In the event of a breakout above the upper range, the next resistance on the charts is expected around 24,930. On the other hand, if the index breaks below the lower range, support is expected around 23,000.

Nifty Pharma Index

Last close: 12,911.35

Based on the hourly charts, there has been a negative breakdown in the index, suggesting that both the index and its constituents are likely to face downward pressure in the near term. Traders and investors should be cautious.

Support levels on the charts are expected around 12,690, 12,575, and 12,450. These levels could potentially act as a floor for the index during its decline. Technical indicators such as RSI, Stochastic, and MACD are all showing a downward slope, indicating bearish momentum in the index.

This further supports the negative outlook. For traders, it is recommended to sell on any rise in the index, while maintaining a strict stop loss of 13,100. This will help manage the risk in case of any unexpected upward movement.

In summary, the Nifty Pharma Index is currently showing signs of weakness on the hourly charts. Traders should be cautious and consider selling on rallies, while maintaining a stop loss at 13,100.

(Ravi Nathani is an independent technical analyst. Views expressed are personal).
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Stock MarketNifty PharmaMarketsMarket technicalsDaily technicalstechnical analysistechnical calls

First Published: Jun 09 2023 | 7:11 AM IST

Next Story